Statera BioPharma (FRA:7CB) Other Current Receivables: €0.18 Mil (As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Other Current Receivables?

Statera BioPharma FRA:7CB 20 Other Current Receivables is €0.18 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Other Current Receivables for the quarter that ended in Sep. 2022 was €0.18 Mil.

Statera BioPharma's quarterly Other Current Receivables increased from Mar. 2022 (€0.08 Mil) to Jun. 2022 (€0.19 Mil) but then stayed the same from Jun. 2022 (€0.19 Mil) to Sep. 2022 (€0.18 Mil).

Statera BioPharma's annual Other Current Receivables increased from Dec. 2019 (€0.00 Mil) to Dec. 2020 (€0.27 Mil) but then declined from Dec. 2020 (€0.27 Mil) to Dec. 2021 (€0.12 Mil).

Statera BioPharma Other Current Receivables Related Terms

Statera BioPharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Other Current Receivables Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Other Current Receivables
0.00 0.27 0.12

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.12 0.08 0.19 0.18
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.18 Mil mean?
Statera BioPharma (FRA:7CB) has a Other Current Receivables of €0.18 Mil as of Sep. 2022. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Other Current Receivables too high?
Statera BioPharma's current Other Current Receivables is €0.18 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Other Current Receivables compare to NRBO and PALI?
Statera BioPharma's Other Current Receivables of €0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Other Current Receivables is €0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Other Current Receivables of €0.18 Mil. The current Other Current Receivables is €0.18 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Other Current Receivables is €0.18 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price